Sotatercept: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Sotatercept. Educational only — not medical advice.
Labeled uses
WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death [see Clinical Studies (14.1) ] .
Source: FDA labeling via NIH DailyMed (set 21693ee2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.